New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
16:12 EDTRCPTReceptos says Phase 2 study of RPC1063 met primary efficacy endpoint
Receptos announced that the Phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis met the primary endpoint, reduction in MRI brain lesion activity. The overall safety profile of RPC1063 was consistent with the results of prior trials, and continues to support the differentiation of the drug candidate against other oral agents for treatment of RMS on the market or in clinical development.
News For RCPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
08:04 EDTRCPTReceptos initiates SUNBEAM Phase 3 Trial of RPC1063
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use